Johnson & Johnson, employing approximately 110,300 people worldwide, is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. Johnson & Johnson's primary interest, both historically and currently, has been in products related to health and well-being. Johnson & Johnson was organized in the State of New Jersey in 1887. 

Fondé en 1887, Johnson & Johnson est l'un des premiers groupes pharmaceutiques mondiaux. 
- produits pharmaceutiques . Johnson & Johnson développe et commercialise des médicaments destinés au traitement des pathologies suivantes : maladies cardio-vasculaires, oncologie, maladies gastro-intestinales, immunologie, neurologie, dermatologie, contraception ...
- produits professionnels . J&J développe, fabrique et commercialise des produits et équipements médicaux destinés aux professionnels de la santé : systèmes de diagnostics, produits orthopédiques, produits de gynécologie, matériel chirurgical, ...
 -produits de grande consommation  : médicaments OTC, nutrition, soins de la personne (marques RoC, Neutrogena, etc.), ophtalmologie (1er producteur mondial de lentilles de contacts avec la marque Acuvue), hygiène féminine, soins bébé, ...

http://www.jnj.com

Sales growth reflects the strong performance of TOPAMAX, an antiepileptic and a treatment for the prevention of migraine headaches; VELCADE, a treatment for multiple myeloma; RISPERDAL CONSTA, an antipsychotic medication; and REMICADE in the U.S., a biologic approved for the treatment of a number of immune mediated inflammatory diseases. 

Growth was negatively impacted by lower sales of PROCRIT, a product for the treatment of anemia, due to a decline in the market. Sales results of RISPERDAL Oral, an antipsychotic medication, were negatively impacted by generic competition outside the U.S. and slowing sales ahead of the loss of marketing exclusivity on June 29, 2008, in the U.S. On June 30, 2008, the Company announced the launch of an authorized generic version of RISPERDAL Oral. 

Johnson & Johnson Announces Dividend Increase of 10.8%
NEW BRUNSWICK, N.J., April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --  Johnson & Johnson today announced that its Board of Directors has declared a 10.8% increase in the quarterly dividend rate, from $.415 per share to $.46 per share. The increase was announced this morning at the Annual Shareholders Meeting in New Brunswick, NJ. 
"In recognition of our solid results in 2007, our strong financial position, and our confidence in the future of Johnson & Johnson, the Board has voted to increase the dividend for the 46th consecutive year," said William C. Weldon, Chairman and Chief Executive Officer of the Company.
At the new rate, the indicated dividend on an annual basis is $1.84 per share compared to the previous rate of $1.66 per share. The next quarterly dividend is payable on June 10, 2008 to shareholders of record as of May 27, 2008. 

Johnson & Johnson Reports 2008 First-Quarter Results:
Sales of $16.2 Billion Increased 7.7% Versus a Year Ago; EPS was $1.26 Excluding 2007 Special Charges, 2008 First-Quarter EPS Increased 8.6%*
NEW BRUNSWICK, N.J., April 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --  Johnson & Johnson today announced record sales of $16.2 billion for the first quarter of 2008, an increase of 7.7% as compared to the first quarter of 2007. Operational growth was 2.6% and currency contributed 5.1%. Domestic sales were up 2.8%, while international sales increased 13.7%, reflecting operational growth of 2.4% and a positive currency impact of 11.3%. 
Net earnings and diluted earnings per share for the first quarter of 2008 were $3.6 billion and $1.26, respectively. The first quarter of 2007 included an after-tax in-process research and development charge of $807 million associated with the acquisition of Conor Medsystems, Inc. Excluding this charge, net earnings for the current quarter and diluted earnings per share represent increases of 6.4% and 8.6%, respectively, as compared to the same period in 2007. * The Company raised its earnings guidance for full-year 2008 to $4.40 - $4.45 per share, which does not include the impact of any in- process research and development charges or other special items. 
"We achieved solid earnings in the first quarter which reflects our continued focus on profitable growth for Johnson & Johnson," said William C. Weldon, Chairman and Chief Executive Officer. "Our strategy of being broadly based remains one of the keys to our consistent long-term performance." 
Worldwide Consumer sales of $4.1 billion for the first quarter represented a 16.2% increase over the prior year with operational growth of 9.9% and a positive impact from currency of 6.3%. Domestic sales increased 11.7%, while international sales increased 20.2% (8.3% from operations and 11.9% from currency). 
Sales results reflect the strong performance of the U.S. launch of ZYRTEC, an over-the-counter allergy treatment; LISTERINE antiseptic mouthrinse and whitening products; Baby Care products; and the skin care lines of NEUTROGENA, CLEAN & CLEAR, and AVEENO. 
Worldwide Pharmaceutical sales of $6.4 billion for the first quarter represented an increase over the prior year of 3.3% with an operational decline of .6% and a positive impact from currency of 3.9%. Domestic sales increased .9%, while international sales increased 7.9%, which reflected an operational decline of 3.1% and a positive currency impact of 11.0%. 
Sales growth reflects the strong performance of REMICADE, a biologic approved for the treatment of a number of immune mediated inflammatory diseases; VELCADE, a treatment for multiple myeloma; RISPERDAL CONSTA outside the U.S., an antipsychotic medication; and CONCERTA, a treatment for attention deficit hyperactivity disorder. 
Growth was negatively impacted by lower sales of PROCRIT, a product for the treatment of anemia, due to a decline in the market. Generic competition in certain markets also impacted sales results for RISPERDAL Oral, an antipsychotic medication, and DURAGESIC, a transdermal patch for chronic pain. In addition, ACIPHEX/PARIET, a proton pump inhibitor for gastrointestinal disorders, was negatively impacted by generic launches of competitive products in this market. 
During the quarter, the Company announced that it received an approvable letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections. 
The Company also submitted a New Drug Application to the FDA for tapentadol hydrochloride immediate release tablets, an investigational oral analgesic for the relief of moderate to severe acute pain. In addition, the Company submitted a Marketing Authorization Application to the European Medicines Agency requesting the approval of golimumab (CNTO 148) as a monthly subcutaneous treatment for adults with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. 
Worldwide Medical Devices and Diagnostics sales of $5.7 billion for the first quarter represented a 7.2% increase over the prior year with operational growth of 1.4% and a positive impact from currency of 5.8%. Domestic sales increased .2%, while international sales increased 13.8% (2.6% from operations and 11.2% from currency). 
Primary contributors to the operational growth included Vistakon's disposable contact lenses; Ethicon Endo-Surgery's minimally invasive products; LifeScan's blood glucose monitoring and Animas's insulin delivery products. Growth was negatively impacted by lower sales of drug-eluting stents in our Cordis franchise due to new competitive entries as well as a decline in the market versus the prior year. 
During the quarter, the Company submitted a Premarket Approval application to the FDA for the SEDASYS System, the first computer-assisted personalized sedation system. 

Johnson & Johnson Reports Fourth-Quarter and Full-Year 2007 Results
2007 Fourth-Quarter Sales of $16.0 Billion increased 16.6%; EPS of $.82 2007 Full-Year Sales of $61.1 Billion increased 14.6%; Full-Year EPS of $3.63 Excluding Special Items, 2007 Fourth-Quarter EPS of $.88 Rose 8.6% And Full-Year EPS of $4.15 Rose 10.4% * 
NEW BRUNSWICK, N.J., Jan 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --  Johnson & Johnson today announced record sales of $16.0 billion for the fourth quarter of 2007, an increase of 16.6% as compared to the fourth quarter of 2006. Operational growth was 11.9% and currency contributed 4.7%. Domestic sales were up 9.1%, while international sales increased 25.8%, reflecting operational growth of 15.3% and a positive currency impact of 10.5%. Worldwide sales for the year 2007 were $61.1 billion, an increase of 14.6% over 2006. Operational growth was 11.5% with currency contributing 3.1%. On a proforma basis, including the net impact of the acquisition of Pfizer Consumer Healthcare in both periods, worldwide sales increased operationally 4.6% and 4.2% for the fourth-quarter and full-year 2007, respectively. 
Net earnings and diluted earnings per share for the fourth quarter of 2007 were $2.4 billion and $.82 respectively, representing increases of 9.5% and 10.8% respectively, compared to the same period in 2006. Net earnings for the fourth quarter of 2007 included an after-tax, non-cash charge of $441 million for the write-down of the intangible asset related to NATRECOR (nesiritide) and a tax gain of $267 million associated with the restructuring of certain international subsidiaries. Net earnings for the fourth quarter of 2006 included an after-tax charge for in-process research and development of $217 million associated with the acquisition of Pfizer Consumer Healthcare. Excluding these special items, 2007 fourth-quarter net earnings were $2.5 billion and earnings per share were $.88, representing increases of 6.8% and 8.6%, respectively, as compared with the same period in 2006. * 
Net earnings and diluted earnings per share for the year, as reported, were $10.6 billion and $3.63, decreases of 4.3% and 2.7%, respectively, as compared with 2006. Full-year 2007 net earnings included after-tax charges of $807 million for in-process research and development; $528 million for restructuring; an after-tax, non-cash charge of $441 million for the write- down of the intangible asset related to NATRECOR (nesiritide); and a gain of $267 million for international tax restructuring. Full-year 2006 net earnings included after-tax charges for in-process research and development of $448 million and an after-tax gain of $368 million associated with the termination of the Guidant acquisition agreement. Excluding these special items, net earnings for 2007 were $12.1 billion and earnings per share were $4.15, representing increases of 8.6% and 10.4%, respectively, as compared with the 
 same period in 2006. * The Company announced its earnings guidance for full- year 2008 of $4.39 to $4.44 per share, which excludes the impact of in-process research and development charges or other special items. 
"Despite challenges in certain markets, our broad base of businesses allowed us to achieve solid results in 2007, building on our foundation of long-term profitable growth," said William C. Weldon, Chairman and Chief Executive Officer. "It was a year of significant progress in our pipeline; the successful integration of Pfizer Consumer Healthcare; and the creation of new organizational structures focused on future growth." 
Worldwide, the Medical Devices and Diagnostics segment achieved annual sales of $21.7 billion in 2007, representing an increase over the prior year of 7.2% with operational growth of 3.9% and a positive currency impact of 3.3%. Domestic sales increased 3.2%, while international sales increased 11.1% (4.6% from operations and 6.5% from currency).